Lexicon Pharmaceuticals
Home
Contact Us
Site Map
About Us
About Us Home
Management Team
Board of Directors
Development Team
Locations
Contact Us
History
Pipeline
Drug Pipeline Home
Our Goal
Therapeutic Areas
Drug Development Team
Clinical Trials
Publications
Discovery
Discovery Home
Discovery Process
Technology
Genome5000
Medicinal Chemistry
Patents
Academic Access
Technology Licensing
Scientific Publications
Alliances
Alliances Home
Current Alliances
Technology Licensing
Careers
Careers Home
Opportunities
Our Culture
Benefits
Community Involvement
The Woodlands
Princeton
Awards and Recognition
News
News Home
Media Inquiries
Investors
Investors Home
Media
Events
Stock Quote
SEC Filings
Annual Reports
Corporate Governance
Request Information
News Home
Media Inquiries
Subscribe
Press Releases
Filter
Display #
5
10
15
20
25
30
50
100
All
01/09/2012
LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
01/04/2012
Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
12/23/2011
Lexicon Announces Completion of Rights Offering to Stockholders
11/22/2011
Lexicon Announces Commencement of Rights Offering to Stockholders
11/11/2011
Lexicon Announces Plans for Rights Offering to Stockholders
11/09/2011
LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
11/03/2011
Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
11/01/2011
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
10/27/2011
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
10/21/2011
Data from Phase 2 Clinical Studies of Telotristat Etiprate in Patients with Carcinoid Syndrome to Be Presented at North American Neuroendocrine Tumor Society Meeting
«
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
»
Page 1 of 41
